

<sup>1</sup> 김도형<sup>1</sup>, 황수희<sup>1</sup>, 전두수<sup>1</sup>, 민진홍<sup>1</sup>, 강형석<sup>1</sup>, 박승규<sup>1,2</sup>

## Clinical Manifestations of Persistent Smear Positive and Culture Negative Sputum Tests 5 Months after First-line Anti-Tuberculous Chemotherapy

Do Hyung Kim, M.D.<sup>1</sup>, Su Hee Hwang, M.D.<sup>1</sup>, Du Su Cheon, M.D.<sup>1</sup>, Jin Hong Min, M.D.<sup>1</sup>, Hyung Seok Kang, M.D.<sup>1</sup>, Seung Gyu Park, M.D.<sup>1,2</sup>

<sup>1</sup>National Masan Hospital, Masan, <sup>2</sup>International Tuberculosis Research Center, Masan, Korea

**Background:** It is not known with certainty whether patients with persistently positive sputum smear results who have also had negative sputum culture results require prolongation of treatment for tuberculosis in order to avoid an increased risk of eventual relapse. The purpose of the present study was to retrospectively describe the treatment characteristics and evaluate the appropriate duration of treatment in these patients.

**Methods:** Sixty of 69 patients with sputum smear positive and culture negative tests at 5 months after first line anti-tuberculous chemotherapy from 2002 to 2003 were retrospectively analyzed. Exclusion criteria included incomplete treatment or resistance to rifampicin or two additional antibiotics, as determined by a drug susceptibility test (DST).

**Results:** Smear conversion of the study subjects was observed after  $8.3 \pm 2.3$  months treatment, and the patients were culture negative after  $2.0 \pm 0.8$  months. The relapse rates of the study subjects were 3.8, 10.0, and 25.8% after 1, 2, and 5 years of anti-tuberculosis chemotherapy, respectively. The relapse rates were not significantly affected by a series of risk factors such as age, sex, presence of diabetes, a sputum culture examination after 2 months treatment, previous treatment history, chest radiograph, and duration of the treatment ( $p > 0.05$ ).

**Conclusion:** Regimen change is not required for patients with persistent smear positive but culture negative tests in the fifth month for first line antituberculous treatment. However, a further study will be needed to clarify the high relapse rate in this specific group of patients. (*Tuberc Respir Dis* 2007;63:417-422)

**Key Words:** Pulmonary tuberculosis, Acid-fast bacilli, Relapse

서 론  
 가 5 가 2007  
 가 2.  
 5~6 3~4  
 가 3, 5  
 가 2~5% 46  
 5~6

Address for correspondence: Seung Gyu Park, M.D.  
 National Masan Hospital, 486, Gapo-dong, Masan 631-710,  
 Korea  
 Phone: 82-55-249-3777, Fax: 82-55-242-1135  
 E-mail: amnon@gsnd.net

Received: Oct. 25, 2007

Accepted: Nov. 14, 2007

가  
 5

대상 및 방법

2002 1 1 2003 12 31

5

가

2가

가

가 (National Tuberculosis Association)

2 isoniazid (INH), rifampicin (RFP), ethambutol (EMB), pyrazinamide (PZA), INH, RFP, EMB

2 PZA

8

± SPSS (version 15.0, SPSS Inc, Chicago, Illinois, USA)

가

가 Kaplan-Mier log rank test

결 과

1,717 5

111 , 1 69

가 60

3

가

3 2 9 2

, 1 12

3 (Table 1).

8 19 11.6±2.0

가 (National Tuberculosis Association) 7 3.3±2.1 (Table 1).

INH 3 2 12 PZA

1 9 가 INH, RMP, EMB

48±16 , 50

(83%) 14 (23%)

46 (77%) , 12

9 40 25.8±8.7 ,

48 38.9±

20.7 (Table 2).

8.3±2.3 ,

Table 1. Treatment characteristics of the study subjects

TD after SC*	Treatment duration (months)					
	8	9	10	11	12	≥13
<0	0	2	0	0	1	0
0~2	1	5	0	1	6	3
3~5	0	6	3	0	18	4
≥6	0	0	0	0	8	2

\*TD after SC means treatment duration after smear conversion (months).

Table 2. Demographic characteristics of the study subjects

	Non-relapse (n=48)(%)	Relapse (n=12)(%)
Age (years)	49.0±16.4	48.5±12.9
Male	39 (81)	11 (92)
DM	11 (23)	3 (25)
Patient category		
New	37 (77)	9 (75)
Relapse	4 (8)	3 (25)
Return after default	7 (15)	0 (0)
Treatment duration (month)	11.6±2.3	11.5±1.2
Follow-up duration (month)	38.9±20.7	25.8±8.7*

\*means relapse time.

2.0±0.8, 2  
 17 (28%), 37 (62%)  
 가 2+ 20 (33%) (Table 3).  
 가 49 (81%)  
 (Table 4).  
 1 3.8%, 2 10%, 3 23.2%,

4 25.8%, 40  
 2  
 (p > 0.05)(Table 5).  
 12 18 (30%), 12 42  
 (70%), 2, 10

Table 3. Laboratory findings of the study subjects

	Non-relapse (n=48)(%)	Relapse (n=12)(%)
Smear conversion time (month)	8.2±2.1	8.9±2.8
Culture conversion time (month)	2.1±0.8	2.0±0.6
Positive sputum culture at 2 months of treatment	15 (31)	2 (17)
Drug susceptibility test		
Pansensitive	29 (61)	8 (67)
INH resistant	1 (2)	2 (17)
EMB resistant	2 (4)	0 (0)
Unknown	16 (33)	2 (17)
Negative sputum smear at completion of treatment	47 (98)	10 (83)
TD after SC*		
≥2	42 (88)	8 (67)
<2	6 (12)	4 (33)
Initial AFB smear		
1+	7 (15)	4 (33)
2+	16 (33)	4 (33)
3+	10 (21)	2 (17)
Unknown	15 (31)	2 (17)

\*TD after SC means treatment duration after smear conversion (months).

Table 4. Radiologic findings of the study subjects

	Non-relapse (n=48)(%)	Relapse (n=12)(%)
Classification*		
Minimal	0 (0)	1 (8)
Moderate advanced	8 (17)	2 (17)
Far advanced	40 (83)	9 (75)
Bilaterality of lesion	38 (79)	11 (92)
Involvement of greater than one lung zone	34 (71)	7 (58)
Cavity	11 (23)	3 (25)
Residual Cavity	22 (46)	6 (50)

\*classification according to National Tuberculosis Association.

Table 5. Analysis of risk factors for relapse

	Cumulative relapse-free proportion (%) at			p-value <sup>†</sup>
	1 year	2 years	5 years	
Overall (cases)	96.2 (50)	90.0 (42)	74.2 (6)	
Age				
≥40 years	97.1	87.2	69.2	0.32
<40 years	94.7	94.7	82.5	
Sex				
Male	95.6	88.4	72.1	0.45
Female	100	100	85.7	
DM				
Yes	100	87.5	62.5	0.41
No	95.2	90.3	76.5	
Culture status at 2 months of treatment				
Negative	94.6	89.5	71.7	0.52
Positive	100	91.7	83.3	
Previous tuberculosis history				
New	97.5	89.5	75.2	0.92
Retreatment	92.3	92.3	71.2	
Disease extent				
Far advanced	100	90.0	68.6	0.58
Moderate advance or minimal	97.7	90.1	75.6	
Cavity				
Yes	100	100	75.2	0.75
No	97.5	86.5	74.1	
Residual cavity				
Yes	91.7	82.5	72.2	0.52
No	100	96.3	76.5	
Drug susceptibility test				
INH resistant	50.0	50.0	100	0.01
Pansensitive	100	90.3	73.4	
TD after SC*				
≥2	95.5	93.1	79.2	0.06
<2	100	75.0	50.0	
Treatment duration				
≥12 months	94.5	85.6	68.0	0.18
<12 months	100	100	86.7	

\*TD after SC means treatment duration after smear conversion (months). <sup>†</sup>p value by log rank test.

(p=0.18). 5  
77%가 가 가 1

42 (70%) 18 (30%) 가 가

INH 가 5 , , ,

26.6%, 100% 가 3 2 , HIV

(p=0.01) INH 가 3 (Table 3). 9, Tam 14

2 50 (83%) 2 가 5 2%

5 79.2%, 50% 11% .

(p=0.06)(Table 4).

고 찰

INH PZA

5 15, Koh 16

가 1 2.1%

가 3 INH 가 3

가 18 (30%)

(selection bias)

2 , , , , 12 ,

가 4,17. Vidal 5

2 , INH ,

Al-Moamary 4 13

6~48 11 1 2

가 9 .

3+ 가 가 , ,

1% 가 가 , ,

PZA 6 10 . 가 가

4.3% 2 95% 가 가

1 3.8% 2 , HIV ,

4 25.8% 11 ,

1 12, Verver 13

가 .

5

가

가

요 약

연구배경: 5

방 법: 2002 1 1 2003 12 31

결 과: 60

8.3±2.3

2.0±0.8

14 (23%), 46 (77%),

가 37 (62%),

가 49 (81%)

1 3.8%, 2 10%, 5 25.8%

2

결 론: 5

가

가

### 참 고 문 헌

1. British Thoracic Association. A controlled trial of six months chemotherapy in pulmonary tuberculosis. First report: results during chemotherapy. *Br J Dis Chest* 1981;75:141-53.
2. Korea Center for Disease Control & Prevention. 2007 Tuberculosis. Seoul: Korea Center for Disease Control & Prevention; 2007.

3. Kim TC, Blackman RS, Heatwole KM, Kim T, Rochester DF. Acid-fast bacilli in sputum smears of patients with pulmonary tuberculosis. *Am Rev Respir Dis* 1984;129:264-8.
4. Al-Moamary MS, Black W, Bessuille E, Elwood RK, Vedal S. The significance of the persistent presence of acid-fast bacilli in sputum smears in pulmonary tuberculosis. *Chest* 1999;116:726-31.
5. Vidal R, Martin-Casabona N, Juan A, Falgueras T, Miravittles M. Incidence and significance of acid fast bacilli in sputum smears at the end of antituberculous treatment. *Chest* 1996;109:1562-5.
6. Sundaram V, Fujiwara PI, Driver CR, Osahan SS, Munsiff SS. Yield of continued monthly sputum evaluation among tuberculosis patients after culture conversion. *Int J Tuberc Lung Dis* 2002;6:238-45.
7. National Tuberculosis Association of the USA. Diagnostic standards and classification of tuberculosis. New York: National Tuberculosis Association; 1961.
8. Veen J, Raviglione M, Rieder HL, Migliori GB, Graf P, Grzemska M, et al. Standardized tuberculosis treatment outcome monitoring in Europe. Recommendations of a Working Group of the World Health Organization (WHO) and the European Region of the International Union Against Tuberculosis and Lung Disease (IUATLD) for uniform reporting by cohort analysis of treatment outcome in tuberculosis patients. *Eur Respir J* 1998;12:505-10.
9. Guler M, Unsal E, Dursun B, Aydin O, Capan N. Factors influencing sputum smear and culture conversion time among patients with new case pulmonary tuberculosis. *Int J Clin Pract* 2007;61:231-5.
10. Chang SC, Yoon YM, Hong YP. Relapse rates within one year after the completion of treatment with short course chemotherapy for pulmonary tuberculosis under programme conditions. *Tuberc Respir Dis* 1987;34:137-43.
11. Frieden T. *Toman's Tuberculosis: case detection, treatment, and monitoring - questions and answers*. 2nd ed. Geneva: World Health Organization; 2004.
12. Panjabi R, Comstock GW, Golub JE. Recurrent tuberculosis and its risk factors: adequately treated patients are still at high risk. *Int J Tuberc Lung Dis* 2007;11:828-37.
13. Verver S, Warren RM, Beyers N, Richardson M, van der Spuy GD, Borgdorff MW, et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. *Am J Respir Crit Care Med* 2005;171:1430-5.

14. Tam CM, Chan SL, Kam KM, Goodall RL, Mitchison DA. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures. *Int J Tuberc Lung Dis* 2002; 6:3-10.
  15. Ormerod LP, Horsfield N, Green RM. Can a nine-month regimen be used to treat isoniazid resistant tuberculosis diagnosed after standard treatment is started? *J Infect* 2001;42:1-3.
  16. Koh WJ, Kwon OJ, Yu CM, Jeon K, Kim KC, Lee BH, et al. Treatment of isoniazid-resistant pulmonary tuberculosis. *Tuberc Respir Dis* 2004;56:248-60.
  17. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/ Infectious Diseases Society of America: treatment of tuberculosis. *Am J Respir Crit Care Med* 2003;167: 603-62.
-